Composition and method for preventing or treating sars-cov-2 infection
AssigneeNational Yang Ming Chiao Tung University
InventorsChia-Ching CHANG, Chia-Yu CHANG, Shin-Ru SHIH, Sheng-Yu HUANG
Life of this patent
Estimating the term…
Abstract
Provided is a non-natural polypeptide including a fragment of major histocompatibility complex class I (MHC I). Also provided are a method for inhibiting combination between SARS-COV-2 and a cell of a subject and a method for preventing or treating SARS-COV-2 infection in a subject in need thereof, including contacting the cell or administering to the subject with the non-natural polypeptide.
Claims20
A method for inhibiting combination between SARS-COV-2 and a cell of a subject in need thereof, comprising contacting the cell with an effective amount of a non-natural polypeptide including a fragment of major histocompatibility complex class I (MHC I).
A method for preventing or treating SARS-COV-2 infection in a subject in need thereof, comprising administering to the subject a pharmaceutical composition, wherein the pharmaceutical composition comprises an effective amount of a non-natural polypeptide including a fragment of major histocompatibility complex class I (MHC I) and a pharmaceutically acceptable carrier thereof.
A non-natural polypeptide having at least 70% sequence identity to at least one of SEQ ID NOs:
- 1, 2, 3, 4, 5, or 6, and showing binding activity to a spike protein receptor binding domain of SARS-COV-2.
Dependencies are inferred from the claim text.